T. Dimopoulos

发表

A combination therapy of dexamethasone and somatostatin analog reintroduces objective clinical responses to LHRH analog in androgen ablation-refractory prostate cancer patients.

C. Mitsiades, M. Koutsilieris, T. Dimopoulos, 2001, The Journal of clinical endocrinology and metabolism.

Combined androgen blockade therapy can convert RT-PCR detection of prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA) transcripts from positive to negative in the peripheral blood of patients with clinically localized prostate cancer and increase biochemical failure-free s

M. Koutsilieris, P. Msaouel, T. Dimopoulos, 2007, Clinical chemistry and laboratory medicine.

Novel concept of antisurvival factor (ASF) therapy produces an objective clinical response in four patients with hormone‐refractory prostate cancer: Case report

M. Koutsilieris, M. Tzanela, M. Tzanela, 1999, The Prostate.

Conversion of nested reverse-transcriptase polymerase chain reaction from positive to negative status at peripheral blood during androgen ablation therapy is associated with long progression-free survival in stage D2 prostate cancer patients.

C. Mitsiades, M. Koutsilieris, T. Dimopoulos, 2001, Anticancer research.

Randomized controlled clinical trial of a combination of somatostatin analog and dexamethasone plus zoledronate vs. zoledronate in patients with androgen ablation-refractory prostate cancer.

C. Mitsiades, M. Koutsilieris, T. Dimopoulos, 2006, Anticancer research.

Combination therapy using LHRH and somatostatin analogues plus dexamethasone in androgen ablation refractory prostate cancer patients with bone involvement: a bench to bedside approach

M. Koutsilieris, R. Tenta, T. Dimopoulos, 2006, Expert opinion on investigational drugs.

A combination therapy of dexamethasone and somatostatin analog reintroduces objective clinical responses to LHRH analog in androgen ablation-refractory prostate cancer patients.

C. Mitsiades, M. Koutsilieris, T. Dimopoulos, 2001, The Journal of clinical endocrinology and metabolism.

Combination of dexamethasone and a somatostatin analogue in the treatment of advanced prostate cancer

C. Mitsiades, M. Koutsilieris, T. Dimopoulos, 2002, Expert opinion on investigational drugs.

Combination of Somatostatin Analog, Dexamethasone, and Standard Androgen Ablation Therapy in Stage D3 Prostate Cancer Patients with Bone Metastases

C. Mitsiades, M. Koutsilieris, T. Dimopoulos, 2004, Clinical Cancer Research.

RANDOMISED CONTROLLED CLINICAL TRIAL OF A COMBINATION OF SOMATOSTATIN ANALOG AND DEXAMETHASONE PLUS ZOLEDRONATE VS. ZOLEDRONATE IN PATIENTS WITH ANDROGEN ABLATION REFRACTORY PROSTATE CANCER

C. Mitsiades, M. Koutsilieris, T. Dimopoulos, 2006 .